InterCure Ltd. (INCR) Stock Price & Growth Analysis

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

InterCure Ltd.

INCR

NASDAQ

70M

Drug Manufacturers - Specialty & Generic

Next Earning date - 28 Apr 2025

70M

Drug Manufacturers - Specialty & Generic

Next Earning date - 28 Apr 2025

1.48USD

0.12 ( 8.82%)

Market Closed (as of Apr 25, 20:00 EDT)

Relative Strenght

Volume Buzz

-24%

Earning Acce

Dist 52w H.

60%

Overview Chart

Quote Panel

Updated April 28, 2025

1W 7.25 % 1M 5.71 % 3M -11.90 % 1Y -43.51 %

Key Metrics

Market Cap
69.80M
Shares Outstanding
47.16M
Share in Float
27.16M
Dividende
0

Earning Date
28 Apr 2025
Price Target
1.48
Average Volume
22322
Beta
0.493

Range
1.17-3.72
Industry
Drug Manufacturers - Specialty & Generic
Website
https://www.intercure.co
Sector
Healthcare

Quote Panel

Updated April 28, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
Shares Outstanding
Share in Float
Dividende

Earning Date
No Data
Price Target
Average Volume
Beta

Range
Industry
Website
Sector

Fundamentals

13.70x

P/E Ratio

1.33x

P/S Ratio

0.58x

P/B Ratio

0.3

Debt/Equity

-16.1%

Net Margin

$-0.4

EPS

How INCR compares to sector?

P/E Ratio

Fundamentals

Relative Strength

INCR

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Relative Strength

INCR

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$1B

1838%

2024-Revenue

$307M

-4368%

2024-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

Canaccord Genuity

upgrade

Previous: Not converted

2022-05-17

Now: Buy

Forecast

Analyst rating

Last analyst upgrade/downgrade

Earnings Growth

YoY

Current

Estimates

Q2.22

-17%

0.1
vs 0.12

Q3.22

+600%

0.05
vs -0.01

Q4.22

+350%

0.05
vs -0.02

Q1.23

-91%

0.01
vs 0.11

Q2.23

-70%

0.03
vs 0.1

Q3.23

N/A

0.05
vs 0.05

Q4.23

N/A

0.05
vs 0.05

Q1.24

-59%

0
vs 0.01

Q2.24

-87%

0
vs 0.03

Q3.24

+11573%

5.84
vs 0.05

Sales Growth

YoY

Current

Estimates

Q2.22

+111%

95.3M vs 45.2M

Q3.22

+63%

100.6M vs 61.7M

Q4.22

+33%

105.6M vs 79.7M

Q1.23

+22%

106.2M vs 87.2M

Q2.23

+8%

102.4M vs 95.3M

Q3.23

-27%

73.5M vs 100.6M

Q4.23

-30%

73.5M vs 105.6M

Q1.24

-41%

62.9M vs 106.2M

Q2.24

-39%

62.9M vs 102.4M

Q3.24

-3%

71.5M vs 73.5M

Return on Equity

QoQ

Q3.22

+1%

0.01
vs 0.03

Q4.22

+1%

0.01
vs 0.01

Q1.23

+0%

0
vs 0.01

Q2.23

+1%

0.01
vs 0

Q3.23

-7%

-0.07
vs 0.01

Q4.23

-7%

-0.07
vs -0.07

Q1.24

+0%

0
vs -0.07

Q2.24

+0%

0
vs 0

Institutionnal Ownership

QoQ

Q1.23

18
vs 16

13%

Q2.23

19
vs 18

Q3.23

22
vs 19

16%

Q4.23

18
vs 22

-18%

Q1.24

20
vs 18

11%

Q2.24

20
vs 20

Q3.24

21
vs 20

Q4.24

18
vs 21

-14%

Earnings Growth

Latest News

seekingalpha.com

3 hours ago

InterCure: A Cannabis Industry Leader Still Flying Under The Radar

prnewswire.com

8 hours ago

InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility

businesswire.com

8 hours ago

InterCure Announces Expansion of its Strategic partnership with Cookies to Germany

benzinga.com

14 hours ago

Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company

prnewswire.com

18 hours ago

InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak

globenewswire.com

18 hours ago

InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million

Company Description

1.48USD

13.70x

1.33x

0.58x

0.3

-16.1%

$-0.4

$1B

$307M

Earnings Growth

Latest News

$1B

$307M

Company Description

1.48USD

13.70x

1.33x

0.58x

0.3

-16.1%

$-0.4